Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2022 · 10-Q
Revenue$177.35M$177.35M+19.5% vs Q3 2021 Net Income$1.75M$1.75M−91.9% vs Q3 2021 EPS Diluted$0.03$0.03−92.5% vs Q3 2021 Operating Income-$1,523,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$13,694,000— Margins · derivedOperating margin-0.9%−22.8 pt vs Q3 2021
Net margin1.0%−13.5 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 9, 2022 · 40 d after period end